0001437749-26-017156
SEC filingQ1 2026 delivered a sharp revenue decline of 32% to $9.9M from healthcare reimbursement and volume pressures, offset by gross margin expansion to 34.6% and cost reductions that improved operating and net losses versus prior year.
Despite the revenue headwinds, gross profit remained resilient at $3.4 million, down just 1.5% from $3.5 million, expanding the gross margin to 34.6%. This improvement was attributable to an increase in volume of pharmacy contract revenue and higher gross profit per prescription from a shift in dispensing mix and continued margin discipline. These factors demonstrate operational leverage in healthcare even as topline volume softened.
Operating income loss narrowed significantly by 25.7% to -$1.1 million from -$1.5 million, with the operating margin at -11.2%. In response to recent trends, management implemented cost reduction measures aimed at improving operational efficiency and preserving liquidity. This discipline mitigated the revenue decline's impact, narrowing losses and positioning the business for better flow-through in future periods.
Cash flow from operations used $2.6 million, worsening from $2.1 million prior year, driven by timing-related decreases in collections from outstanding receivables. The company expects a portion of these to be collected in Q2 2026, though timing may vary. With zero capital expenditures this quarter versus $22 thousand last year, free cash flow matched operating cash use. Principal cash needs include pharmaceutical and e-Commerce inventory, operating expenses like payroll and professional services, technology investments, and potential acquisitions. An ATM program provides flexible liquidity for working capital and strategic purposes, supporting ongoing operations amid these dynamics.